drugset / Trial / NCT03298906

A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

NCT03298906

Phase 1 Completed 16 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the effects of ticlopidine on the pharmacokinetics (PK) of intranasally administered esketamine.

Timeline

Start
2017-09-26
Primary completion
2017-11-27
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 56 mg Intranasal
Subject ticlopidine Small molecule 250 mg Oral

Indications

No indication recorded.